Home · Health · Sep 15 archive
FDA Launches Pilot Program to Shorten Drug Approval Times
Confirmed
In Short: The Food and Drug Administration (FDA) has announced a pilot program aimed at reducing the time it takes for drugmakers to begin human testing of their products.
The FDA is now accepting applications for the pilot program, which will allow drugmakers to begin human testing more quickly. According to STAT, this initiative is part of a broader effort to shorten the FDA’s drug approval timelines. The program is expected to accelerate the process of bringing new treatments to market, potentially benefiting patients with rare diseases.
In related news, the FDA has approved the first-ever therapy that targets the loss of muscle in spinal muscular atrophy (SMA), a rare neurological disorder. The drug, Isembyld, was developed by Scholar Rock and has shown promising results in clinical trials. "Today’s FDA approval of Isembyld marks a defining moment for the SMA community," said David Hallal, CEO of Scholar Rock, in a press release.
The approval of Isembyld for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement, is a significant milestone. The late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year, while those in a placebo group declined, a difference that was statistically significant.
However, the FDA's recent actions have also faced criticism. In a related development, the agency approved the first mRNA-based vaccine for influenza, made by Moderna. Health experts say the shot could have several advantages over traditional flu vaccines, but its approval comes at a time when federal health agencies have walked back recommending flu vaccines for many people.
The FDA's actions have not been without controversy. In another development, U.S. District Judge Richard Leon ruled that President Trump had no authority to build a ballroom on the White House grounds without the approval of Congress, and he ordered a halt to the above-ground construction. This decision highlights the ongoing challenges the FDA faces in maintaining its authority and credibility.
What's confirmed
- The FDA is now accepting applications for the pilot program, which will allow drugmakers to begin human testing more quickly. According to STAT, this initiative is part of a broader effort to shorten the FDA’s drug approval timelines. The program is expected to accelerate the process of bringing new treatments to market, potentially benefiting patients with rare diseases.
- In related news, the FDA has approved the first-ever therapy that targets the loss of muscle in spinal muscular atrophy (SMA), a rare neurological disorder. The drug, Isembyld, was developed by Scholar Rock and has shown promising results in clinical trials. "Today’s FDA approval of Isembyld marks a defining moment for the SMA community," said David Hallal, CEO of Scholar Rock, in a press release.
- The approval of Isembyld for use in adults and children 2 years and older who are currently receiving SMA therapies that target SMN2, a key gene for neurons that control movement, is a significant milestone. The late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year, while those in a placebo group declined, a difference that was statistically significant.
- However, the FDA's recent actions have also faced criticism. In a related development, the agency approved the first mRNA-based vaccine for influenza, made by Moderna. Health experts say the shot could have several advantages over traditional flu vaccines, but its approval comes at a time when federal health agencies have walked back recommending flu vaccines for many people.
- The FDA's actions have not been without controversy. In another development, U.S. District Judge Richard Leon ruled that President Trump had no authority to build a ballroom on the White House grounds without the approval of Congress, and he ordered a halt to the above-ground construction. This decision highlights the ongoing challenges the FDA faces in maintaining its authority and credibility.
What's still developing
- The pilot was first announced in June as part of Operation TrialBlazer, the Department of Health and Human Services initiative that pledged to shorten the FDA’s drug approval timelines and help the U.S. compete with the rapidly accelerating biotechnology industries in countries like China and Australia.
- Test your knowledge with our new weekday mini crossword Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies.
- Apple is preparing for one of its most important product launches in years, with the company's September 9 event expected to introduce a new generation of premium iPhones, Apple Watches and, potentially, a completely new product category for the company: a foldable iPhone.
- Cognizant has about 3,510 H-1B approvals as of 30 June, according to USCIS data.
- The suspension applies to PERM, or Program Electronic Review Management, the labour-certification process through which US employers seek approval to sponsor foreign workers for permanent residency.
- Access unlimited news content and The Canberra Times app.
- "Yet in the public eye, we are taking five steps backward as trustworthy emissaries for the advancement of science, all due to the undermining of research and our credibility as trusted advisors.” mFlusiva's road to approval exemplifies this now-fraught environment for vaccines in the U.S., after the FDA initially dropped it from review in February.
- With roughly one in six American adults taking an antidepressant medication, Swedish firm Flow Neuroscience is positioning its device as an alternative to traditional drugs.